In a previous study, Chen et al
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
Ridge T, Moretto T, MacConell L, et al
These injectable weight-loss meds, often referred to as GLP1 weight-loss drugs, have gained massive attention for their effectiveness in helping people lose significant weight while also improving blood sugar control
The injection is generally well-tolerated, and most individuals experience minimal discomfort
The rationale for combining ALA and L-carnitine is supported by previous research demonstrating enhanced effects when combining different supplements in migraine management